136 related articles for article (PubMed ID: 6362846)
1. A phase-II trial of Corynebacterium parvum as adjuvant to surgery in the treatment of operable lung cancer.
Woodruff M; Walbaum P
Cancer Immunol Immunother; 1983; 16(2):114-6. PubMed ID: 6362846
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Corynebacterium parvum immunotherapy for squamous cell epitheliomas of the oral cavity, pharynx, and larynx.
Neifeld JP; Terz JJ; Kaplan AM; Lawrence W
J Surg Oncol; 1985 Feb; 28(2):137-45. PubMed ID: 3881630
[TBL] [Abstract][Full Text] [Related]
3. Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. Ludwig Lung Cancer Study Group.
J Thorac Cardiovasc Surg; 1985 Jun; 89(6):842-7. PubMed ID: 2860271
[TBL] [Abstract][Full Text] [Related]
4. Intrapleural and intravenous Corynebacterium parvum in patients with resected stage I and II non-small cell carcinoma of the lung. The Ludwig Lung Cancer Study Group.
Ludwig Lung Cancer Study Group
Cancer Immunol Immunother; 1986; 23(1):1-4. PubMed ID: 2876772
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant intralesional and systemic Corynebacterium parvum immunotherapy for surgically treated head and neck cancer.
Beatty JD; Terz JJ; Brown PW; Lawrence W; Schuller GB; Kaplan AM
Surg Forum; 1978; 29():155-7. PubMed ID: 401122
[No Abstract] [Full Text] [Related]
6. A randomized study of adjuvant immunotherapy with levamisole and Corynebacterium parvum in operable non-small cell lung cancer.
Fox RM; Woods RL; Tattersall MH; Basten A
Int J Radiat Oncol Biol Phys; 1980 Aug; 6(8):1043-5. PubMed ID: 6998933
[No Abstract] [Full Text] [Related]
7. Surgery plus Corynebacterium parvum immunotherapy for Lewis lung carcinoma in mice.
Karrer K; Rella W; Goldin A
Eur J Cancer (1965); 1979 Jun; 15(6):867-73. PubMed ID: 499275
[No Abstract] [Full Text] [Related]
8. [Immunotherapy of lung cancer].
Jassem J; Jassem E
Pol Tyg Lek; 1982 Jun; 37(17):497-9. PubMed ID: 6292882
[No Abstract] [Full Text] [Related]
9. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
[TBL] [Abstract][Full Text] [Related]
10. Phase III study on the treatment of women with cervical cancer, stage IIB, IIIB, and IVA (confined to the pelvis and/or periaortic nodes), with radiotherapy alone versus radiotherapy plus immunotherapy with intravenous Corynebacterium parvum: a Gynecologic Oncology Group Study.
DiSaia PJ; Bundy BN; Curry SL; Schlaerth J; Thigpen JT
Gynecol Oncol; 1987 Mar; 26(3):386-97. PubMed ID: 3549476
[TBL] [Abstract][Full Text] [Related]
11. Lung cancer patients treated with Corynebacterium parvum. Phase I toxicity study.
Yadeau R; Bates HA; Fortuny I
Minn Med; 1979 Sep; 62(9):673-5. PubMed ID: 503003
[No Abstract] [Full Text] [Related]
12. Evaluation of the worth of corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer. Eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-10.
Fisher B; Brown A; Wolmark N; Fisher ER; Redmond C; Wickerham DL; Margolese R; Dimitrov N; Pilch Y; Glass A
Cancer; 1990 Jul; 66(2):220-7. PubMed ID: 2196108
[TBL] [Abstract][Full Text] [Related]
13. Combination chemoimmunotherapy for extensive non-oat cell lung cancer.
Issell BF; Valdivieso M; Hersh EM; Richman S; Gutterman JU; Bodey GP
Cancer Treat Rep; 1978 Jul; 62(7):1059-63. PubMed ID: 356968
[TBL] [Abstract][Full Text] [Related]
14. [The use of Corynebacterium parvum in pleurodesis].
Helin T; Haahtela T
Duodecim; 1988; 104(4):262-5. PubMed ID: 3168834
[No Abstract] [Full Text] [Related]
15. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
Chahinian AP; Goldberg J; Holland JF; Reisman A; Jaffrey IS; Mandel EM
Cancer Treat Rep; 1982 Jun; 66(6):1291-7. PubMed ID: 6282455
[TBL] [Abstract][Full Text] [Related]
16. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
[TBL] [Abstract][Full Text] [Related]
17. Specific and nonspecific immunotherapy as an adjunct to curative surgery for cancer of the lung.
Hollinshead AC; Stewart TH
Yale J Biol Med; 1981; 54(5):367-79. PubMed ID: 7039148
[TBL] [Abstract][Full Text] [Related]
18. Non-specific immunostimulation in bronchogenic cancer.
Israel L
Scand J Respir Dis Suppl; 1974; 89():95-105. PubMed ID: 4370224
[No Abstract] [Full Text] [Related]
19. Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.
Bjornsson S; Takita H; Kuberka N; Preisler H; Catane H; Higby D; Henderson E
Cancer Treat Rep; 1978 Apr; 62(4):505-10. PubMed ID: 350388
[TBL] [Abstract][Full Text] [Related]
20. Studies on antitumor effect of corynebacterium parvum and pustulan on Lewis lung carcinoma in mice.
Budzyński W
Arch Immunol Ther Exp (Warsz); 1982; 30(5-6):379-84. PubMed ID: 7184489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
